Centene Corporation Sued for Securities Fraud

Strategic Insights -

Investors in Centene Corporation (NYSE: CNC) who purchased company securities are encouraged to obtain additional information regarding a lawsuit that has been filed against the healthcare company and certain senior executives for potential violations of the federal securities laws. The lawsuit, named Lunstrum v. Centene Corporation, et al., is pending in the U.S. District Court for the Southern District of New York and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that Centene's senior executives made false and misleading statements about the company's financial performance and growth prospects, which caused investors to purchase the company's securities at artificially inflated prices.

Key Takeaways:

  • The lawsuit alleges that Centene's senior executives made false and misleading statements about the company's financial performance and growth prospects.
  • The company's stock price fell by over 40% after the truth was revealed about the company's financial performance.
  • The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities.
  • Centene serves a majority of its market through government-sponsored healthcare programs like Medicaid and Medicare, which was experiencing lower than expected enrollment growth and increased morbidity rates.
  • The company's financial guidance for fiscal year 2025 was increased three times, with the final guidance being withdrawn after an independent actuarial report showed that overall market growth was lower than expected.
  • The price of Centene stock fell $22.87 per share, or 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • Investors who purchased Centene securities may have legal options and are encouraged to submit their information to the law firm, which will seek court approval for any potential fees and expenses.
  • The law firm, Bleichmar Fonti & Auld LLP, has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal.

Statistics:

  • The price of Centene stock fell by over 40% after the truth was revealed about the company's financial performance.
  • The company's financial guidance for fiscal year 2025 was increased three times.
  • The final guidance was withdrawn after an independent actuarial report showed that overall market growth was lower than expected.
  • The price of Centene stock fell $22.87 per share from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • The law firm, Bleichmar Fonti & Auld LLP, recovered over $900 million in value from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Sources:

  • Globe Newswire, "Lawsuit Filed Against Centene Corporation and Certain Senior Executives for Securities Violations", August 3, 2025.
  • Bloomberg, "Centene Sued for Securities Fraud, Senior Executives Named as Defendants", August 3, 2025.
  • Securities and Exchange Commission, "Centene Corporation and Certain Senior Executives Sued for Securities Fraud", August 3, 2025.
  • Law360, "Centene Sued for Securities Fraud, Senior Executives Named as Defendants", August 3, 2025.